NCT03352934 - Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 7, 2017

Primary Completion Date

February 18, 2022

Study Completion Date

February 18, 2022

Conditions

Cancer

Interventions

DRUG

Avelumab

Avelumab will be administered as intravenous infusion at 10 mg/kg once every two weeks until documented disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawal are met.

Trial Locations (4)

D-06120

Poliklinik für Innere Medizin I Universitätsklinikum Halle, Halle

D-69120

Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg, Heidelberg

D-55131

Schwerpunkt Endokrinologie und Stoffwechselerkrankungen Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

D35043

Klinik für Innere Medizin, Abteilung Gastroenterologie Universitätsklinikum Gießen und Marburg, Marburg

All Listed Sponsors

collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Johannes Gutenberg University Mainz

OTHER